ALK and non-small cell lung carcinoma: With targeted therapy becoming standard practice and the availability of an increasing number of novel therapeutic agents against ALK+ NSCLC, assessing the cost-effectiveness of new therapies has become instrumental in determining the implementation of these strategies.